Alvotech (ALVO) Stock Price, News & Analysis

Company Overview

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Key Stats

• Today's Range: $9.60 to $10.30
• 50-Day Range: $7.84 to $11.66
• 52-Week Range: $7.35 to $14.65
• Volume: 268,212 shs
• Average Volume: 135,895 shs
• Market Capitalization: $3.10 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Buy

Alvotech Stock Analysis - MarketRank™

Alvotech scored higher than 39% of companies evaluated by MarketBeat, and ranked 723rd out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Alvotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alvotech has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alvotech are expected to grow in the coming year, from ($0.07) to $0.20 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alvotech is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alvotech is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.93% of the float of Alvotech has been sold short.

Short Interest Ratio / Days to Cover

Alvotech has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Alvotech has recently increased by 27.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alvotech does not currently pay a dividend.

Dividend Growth

Alvotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.93% of the float of Alvotech has been sold short.

Short Interest Ratio / Days to Cover

Alvotech has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Alvotech has recently increased by 27.12%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.89

News Sentiment

Alvotech has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Alvotech this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for ALVO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Alvotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alvotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.46% of the stock of Alvotech is held by insiders.

ALVO Stock Analysis - Frequently Asked Questions

How have ALVO shares performed this year?

Alvotech's stock was trading at $13.23 on January 1st, 2025. Since then, ALVO stock has decreased by 22.3% and is now trading at $10.28.
View the best growth stocks for 2025 here.

How were Alvotech's earnings last quarter?

Alvotech (NASDAQ:ALVO) announced its quarterly earnings results on Wednesday, May, 7th. The company reported $0.35 earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.52.
Read the conference call transcript.

Who are Alvotech's major shareholders?

Top institutional investors of Alvotech include Vanguard Group Inc. (1.39%), PointState Capital LP (0.39%), Royce & Associates LP (0.06%) and China Universal Asset Management Co. Ltd. (0.02%).

How do I buy shares of Alvotech?

Shares of ALVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alvotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alvotech investors own include Micron Technology (MU), Arista Networks (ANET), United Microelectronics (UMC), Weatherford International (WFRD), NVIDIA (NVDA), PACCAR (PCAR) and Axcelis Technologies (ACLS).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 5/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALVO
• Previous Symbol: NYSE:ALVO
• CIK: 1898416
• Web: www.alvotech.com
• Phone: 354-422-4500
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $18.00
• High Stock Price Target: $18.00
• Low Stock Price Target: $18.00
• Potential Upside/Downside: +75.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.37
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-551,730,000.00
• Net Margins: -123.47%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -35.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.69
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: $585.60 million
• Price / Sales: 5.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 301,482,000
• Free Float: N/A
• Market Cap: $3.10 billion
• Optionable: Not Optionable
• Beta: -0.02